<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920107-0109</DOCNO><DOCID>920107-0109.</DOCID><HL>   Technology:   SmithKline Drug Gets Approval</HL><DATE>01/07/92</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   SBE</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><NS>NEW PRODUCTS andamp; SERVICES (PDT)</NS><GV>FOOD AND DRUG ADMINISTRATION (FDA)</GV><RE>EUROPE (EU)NORTH AMERICA (NME)GREAT BRITAIN (UK)UNITED STATES (US)WESTERN EUROPE (WEU)</RE><LP>   PHILADELPHIA -- SmithKline Beecham PLC said it receivedapproval from the Food and Drug Administration to market itsTriostat medicine to treat myxedema coma and precoma, anextreme thyroid condition.   The medicine, a synthetic injectable form of a thyroidhormone, also was awarded orphan-drug status, which meansSmithKline will have seven-year marketing exclusivity forthis indication of the drug. The disease strikes about 50 to100 Americans each year, primarily women older than 70 beingtreated for hypothyroidism, a thyroid condition.</LP><TEXT/></DOC>